Clinical trials: Hydroxychloroquine
Insulin Resistance
Rediscovering Hydroxychloroquine as a Novel Insulin Sensitizer
Current options to treat insulin resistance in diabetes are fairly limited. For this reason, novel treatments would represent a major progress.
- Trial name
- REHNIS (NCT02124681)
- Testing
- Hydroxychloroquine
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- University of Pittsburgh
COVID19, Coronavirus
Chloroquine/ Hydroxychloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting
The study is a double-blind, randomised, placebo-controlled trial that will be conducted primarily in healthcare settings and other facilities directly involved in COVID-19 case management.
- Conditions
- COVID19, Coronavirus, Acute Respiratory Illnesses
- Trial name
- COPCOV (NCT04303507)
- Testing
- Chloroquine or Hydroxychloroquine
- Where
- 25 sites in Benin, Côte d’Ivoire and 8 more
- Volunteers
- 4,652 people, healthy volunteers welcome
- Sponsor
- University of Oxford
COVID-19
Ivermectin for Severe COVID-19 Management
In this multicenter study; it was aimed to investigate the effectiveness and safety of ivermectin use in the treatment of patients with severe COVID-19 pneumonia that have no mutations which alter ivermectin metabolism and cause…
- Trial name
- NCT04646109
- Testing
- Ivermectin
- Where
- 4 sites in Turkey (Türkiye)
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Afyonkarahisar Health Sciences University
COVID-19
Austrian CoronaVirus Adaptive Clinical Trial (COVID-19)
The Austrian Coronavirus Adaptive Clinical Trial (ACOVACT) is a randomized, controlled, multicenter, open-label basket trial that aims to compare various antiviral treatments for COVID-19.
- Trial name
- ACOVACT (NCT04351724)
- Testing
- Chloroquine or Hydroxychloroquine, Lopinavir/Ritonavir, Best standard of care
- Where
- 9 sites in Austria
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Non-Small Cell Lung Cancer, KRAS Mutation-Related Tumors
Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer
This study will evaluate using hydroxychloroquine (HCQ) along with binimetinib as an effective method for treating cancer. All patients will receive binimetinib at a standard dose approved for other cancers.
- Trial name
- NCT04735068
- Testing
- Binimetinib Pill, Hydroxychloroquine Pill
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Abramson Cancer Center at Penn Medicine